Nordic Bioscience Targets 20% SDV with Risk-Based Monitoring to Streamline Clinical Trial Execution
Add bookmark
This case study shows how Nordic Bioscience, one of Europe’s fastest-growing biotech companies, focused site monitoring efforts with only 20% source document verification (SDV) to improve study data quality.
For further education on achieving reduced SDV and site monitoring costs with a risk-based approach, register for Medidata's upcoming seminar taking place in Stuttgart, Germany on 23 October.
